Implementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia
Long Nguyen-Hoang,Linh Thuy Dinh,Angela S T Tai,Duy-Anh Nguyen,Ritsuko K Pooh,Arihiro Shiozaki,Mingming Zheng,Yali Hu,Bin Li,Aditya Kusuma,Piengbulan Yapan,Arundhati Gosavi,Mayumi Kaneko,Suchaya Luewan,Tung-Yao Chang,Noppadol Chaiyasit,Tongta Nanthakomon,Huishu Liu,Steven W Shaw,Wing Cheong Leung,Zaleha Abdullah Mahdy,Angela Aguilar,Hillary H Y Leung,Nikki M W Lee,So Ling Lau,Isabella Y M Wah,Xiaohong Lu,Daljit S Sahota,Marc K C Chong,Liona C Poon,FORECAST Collaborators,Iok Seng Wong,Yunyu Chen,Jiao Liu,Jing Lin,Ada W T Tse,Lo Wong,Fangzi Liu,Runmei Ma,Jiang Yan Min,Mahesh A Choolani,Tuangsit Wataganara,Osamu Shimokawa
DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.069907
IF: 37.8
2024-10-15
Circulation
Abstract:Background: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. Methods: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. Results: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91-2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37-0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23-0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22-0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12-0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. Conclusions: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03941886.